Insilico Medicine's AI-Designed Inhibitor for IBD (VIDEO)

InSilico Medicine

Caption

Insiilico Medicine has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD) designed by its generative AI platform.

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.